These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 28044942)

  • 1. Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
    Citrome L
    CNS Spectr; 2016 Dec; 21(S1):1-12. PubMed ID: 28044942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three-month paliperidone palmitate - a new treatment option for schizophrenia.
    Bernardo M; Bioque M
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):899-904. PubMed ID: 27206330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
    Kim E; Correll CU; Mao L; Starr HL; Alphs L
    CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
    Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
    Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.
    Pae CU; Wang SM; Han C; Bahk WM; Lee SJ; Patkar AA; Masand PS; Serretti A; Emsley R
    Int Clin Psychopharmacol; 2017 Sep; 32(5):235-248. PubMed ID: 28430670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
    Citrome L
    Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Going the distance: reviewing antipsychotic depot or long-acting injectable treatments in Australasia.
    Theodoros T; Taylor M; Huang HC; Wang N; Motamarri B
    Australas Psychiatry; 2018 Jun; 26(3):303-306. PubMed ID: 29457473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
    Miller BJ; Claxton A; Du Y; Weiden PJ; Potkin SG
    Schizophr Res; 2019 Jun; 208():44-48. PubMed ID: 30745067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
    Weiden PJ; Claxton A; Kunovac J; Walling DP; Du Y; Yao B; Yagoda S; Bidollari I; Keane E; Cash E
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32433835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole Lauroxil: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
    Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
    Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ; Du Y; Liu CC; Stanford AD
    CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
    Corponi F; Fabbri C; Bitter I; Montgomery S; Vieta E; Kasper S; Pallanti S; Serretti A
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):971-985. PubMed ID: 31255396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
    Aggarwal A; Gopalakrishna G; Lauriello J
    Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities.
    Krogmann A; Peters L; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
    CNS Spectr; 2019 Aug; 24(S1):38-69. PubMed ID: 31482779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.